Viewed as a value stock with a valuation floor near revenue/asset levels; long-term gene therapy data for Elevidys looks promising.

The speaker's sentiment shifted from initially negative to cautiously bullish, noting the stock is 'bottoming out pretty well,' suggesting a potential turnaround or that the stock has found a floor.

Briefly mentioned with a continued bullish sentiment, with the speaker stating he 'still like[s] them'.

Noted for having been 'weak in momentum for about six months,' indicating a bearish or cautious stance on the stock's recent performance.

The speaker has a highly contradictory view, at times seeing it as a beaten-down recovery play that could reach $50, while at other times stating they are actively shorting it.

The speaker is 'over the moon about' this stock, making it a high-conviction bullish pick.

Bullish, as the speaker confirms he is 'still in' the stock, indicating a continuing long position.

The speaker is long the stock with a generally positive tone, but is also actively trading it by selling shares on bounces, suggesting a bullish but risk-managed approach.

Speaker had a successful long trade on the stock's 'huge bounce' and 'real nice recovery.' They have taken partial profits but still hold a position.

The speaker is frustrated with the investment's poor performance and highlights significant risks, including internal FDA politics. They advise extreme caution, suggesting it is a highly speculative and difficult area to invest in.